Spherix Announces That Anthony Hayes Joins The Board Of Directors At Hoth Therapeutics Inc.
NEW YORK, July 27, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (NASDAQ: SPEX), an intellectual property development company committed to fostering of technology, today announced that Anthony Hayes, CEO of Spherix Inc., joins the board of directors at Hoth Therapeutics Inc.
As recently announced, Spherix purchased an interest in Hoth Therapeutics, a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from eczema. The appointment to the Hoth board of directors is to give Spherix representation on the board to help protect and foster Spherix's investment.
Anthony Hayes, Spherix CEO, stated "As Hoth continues to grow as a company, this appointment gives Spherix involvement in Hoth to nurture and protect the Spherix investment. The eczema space is exciting and continuing to grow. The July 19, 2017, article in the New York Times by Elizabeth Olson on eczema, demonstrates the substantial demand for treatments for this terrible affliction. We are proud to be part of the effort to solve this medical condition and hopefully bring relief to those suffering."
About Spherix Incorporated
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by participation in the development of new technology. Spherix draws on portfolios of pioneering technology to support product innovation.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. We are a small company with limited financial resources and our scientific background and abilities to implement a commercialization strategy is subject to ever-changing market conditions and rapidly-advancing technologies over which we have no control. While we believe that these forward-looking statements are reasonable, market conditions and competition in the marketplace is ever-changing and we have no control over these influences. As a result, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC") including, but not limited to, the Risk Factors relating to the Company's patent business and other aspects of the Company's business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations Contact:
Hayden IR, LLC
Brett Mass
Phone: (646) 536-7331
Email: investorrelations@spherix.com
www.haydenir.com
Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com
www.spherix.com
View original content with multimedia:http://www.prnewswire.com/news-releases/spherix-announces-that-anthony-hayes-joins-the-board-of-directors-at-hoth-therapeutics-inc-300495096.html
SOURCE Spherix Incorporated
